April 1st 2024
The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.
February 1st 2024
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Stage Is Set for Exploring TNBC, HER2-Positive Settings at 38th Annual CFS
September 23rd 2020Delivering evidence-based state-of-the art cancer care in the management of hematologic and solid malignancies is the mainstay of the 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow conference taking place virtually November 4 through 6, 2020.
Read More
Updated ALTERNATIVE Results Favor Dual HER2 Blockade in HER2+/HR+ Metastatic Breast Cancer
September 22nd 2020“Dual targeting of HER2-positive tumors with [trastuzumab] and [lapatinib] is beneficial because of differing mechanisms of action and because of the well-characterized synergistic interaction between them in HER2 [breast cancer] models."
Read More
Survival Improved With Tucatinib Regimen in HER2-Positive Metastatic Breast Cancer
September 21st 2020Statistically significant and clinically meaningful improvements in both progression-free survival and overall survival were observed with the addition of tucatinib to trastuzumab and capecitabine as treatment of patients with HER2-positive metastatic breast cancer, irrespective of the presence of brain metastases.
Read More
HER2+ Breast Cancer Treatment Approaches Becomes More Individualized
September 16th 2020In an interview with Targeted Oncology, Sara A. Hurvitz, MD, reviewed the 4 currently approved treatment options for patients with HER2-positive breast cancer and discussed how physicians could use the data to make treatment decisions in the adjuvant and neoadjuvant setting.
Read More
HER2CLIMB Regimen Can Be Used Earlier in HER2+ Metastatic Breast Cancer
September 16th 2020Nancy U. Lin, MD, discusses how she would use the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.
Watch
Current Breast Cancer Landscape and Targeted Therapies for HER2 Overexpression
September 16th 2020Breast cancer is the most common cancer that affects women, with estimates that it will account for 30% of all new cancer diagnoses in women in 2020. As the most commonly overexpressed receptor in breast cancer, HER2 is amplified or overexpressed in about 15% of breast cancers, leading to dysregulated cell proliferation. This article explores the current breast cancer landscape, with a focus on emerging HER2-targeted therapies, and discusses the unmet needs within the treatment landscape.
Read More
HER2 Blockade Regimen Appears Superior as Treatment of HER2+ HR+ Metastatic Breast Cancer
August 27th 2020Frontline trastuzumab plus lapatinib and an aromatase inhibitor demonstrated superior progression-free survival compared with the trastuzumab/aromatase inhibitor alone as treatment of patients with HER2-positive, HR-positive metastatic breast cancer.
Read More
The Impact of an Overall Survival Benefit in HER2+ Metastatic Breast Cancer
August 20th 2020In an interview with Targeted Oncology following the conference, Kevin Kalinsky, MD, MS, gave his take on how targeted therapies are impacting the field of HER2-positive metastatic breast cancer, and he interprets the primary data from the phase 2 HER2CLIMB trial.
Read More
Modern Therapies Offer a Way to Reach the Brain in HER2+ Metastatic Breast Cancer
August 14th 2020In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.
Read More